Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris.
Acta Derm Venereol
; 100(17): adv00286, 2020 Oct 06.
Article
en En
| MEDLINE
| ID: mdl-32985675
ABSTRACT
Rituximab targets the B-lymphocyte antigen CD20, providing pemphigus vulgaris patients with long-term remissions. However, the effects of repeated courses have not yet been established. This study aimed to evaluate the effect of repeated rituximab courses on remission length in pemphigus vulgaris. A total of 73 patients with pemphigus vulgaris treated with rituximab at a single centre were retrospectively analysed. Of 73 study participants (28 men, 45 women), 42 (58%) received a 2nd course of rituximab, 24 (33%) received a 3rd course, 4 (6%) received a 4th course, and one (1%) received a 5th course. Rituximab remained efficacious in each course, irrespective of previous treatments (complete remission 75-81%). Following the 2nd and 3rd courses, the results indicated longer remissions with reduced flare-ups, and the remission length increased with each subsequent course. We conclude that rituximab serves as a disease-modifying agent, notably for patients with moderate-to-severe pemphigus vulgaris.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Pénfigo
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Acta Derm Venereol
Año:
2020
Tipo del documento:
Article